



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

Jun 21 2021, 8:30 AM EDT

CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments

Jun 16 2021, 4:01 PM EDT

Nature Communications Publishes Study of CytoDyn's Leronlimab Preventing HIV Infection in Primates

Jun 7 2021, 8:51 AM EDT

Management Team

Nader Z. Pourhassan, Ph.D.

Director, President and CEO

Scott A. Kelly, M.D.

Chief Medical Officer, Head of Business Development and Chairman of the Board

Nitya G. Ray, Ph.D.

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Christopher Recknor, M.D.

Chief Operating Officer and Head of Clinical Development

Antonio Migliarese, C.P.A.

Chief Financial Officer

Arian Colachis, J.D.

Senior Vice President, General Counsel and Corporate Secretary

Michael D. Mulholland

Senior Vice President, Finance

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.